Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90010 added to usual post-surgical treatment for newly diagnosed glioblastoma
NL-OMON60122Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of trotabresib in glioblastoma (GBM), sponsored by Celgene Corporation. Started Dec 2020; status: completed.
02
Drugs
trotabresib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON60122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60122.